RENOVA 0.05% Rx
Generic Name and Formulations:
Tretinoin 0.05%; crm.
Valeant Pharmaceuticals, Inc
Indications for RENOVA 0.05%:
Adjunct to comprehensive skin care and sunlight avoidance programs in the palliation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.
≥18 years: Wash face with mild soap, pat dry and wait 20–30 minutes before use. Apply a small amount to cover entire affected area lightly once daily in the PM. Do not wash face, or use other skin care products for at least 1 hour after application. Discontinue if sensitivity, irritation, or systemic reactions occur.
<18yrs: not recommended.
Do not use on sunburn, eczema, other chronic skin conditions, or for sun-sensitive patients. Avoid eyes, ears, mouth, angle of nose, mucous membranes, sun, UV light. Increased irritation in extreme weather. Elderly. Pregnancy (Cat.C), nursing mothers: not recommended.
Avoid photosensitizers, topical irritants, and drying agents.
Local erythema, peeling, dry skin, burning, stinging, pruritus, hypo- or hyperpigmentation.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy